Literature DB >> 23446106

Incomplete data in randomized dermatology trials: consequences and statistical methodology.

Michael A McIsaac1, Richard J Cook, Melanie Poulin-Costello.   

Abstract

Randomized clinical trials can provide the highest level of evidence regarding the effectiveness of therapeutic interventions. When individuals in trials do not complete the planned treatment period it is often not possible to observe the desired outcomes, which results in incomplete data. Here we review various mechanisms which can lead to incomplete data, discuss the impact of these mechanisms, and present strategies for dealing with incomplete data. We discuss these issues in the context of clinical trials in dermatology and provide practical recommendations for planning and drawing conclusions from studies which could involve incomplete data.
Copyright © 2013 S. Karger AG, Basel.

Mesh：

Substances：

Year:  2013        PMID： 23446106     DOI： 10.1159/000346247

Source DB:  PubMed          Journal:  Dermatology        ISSN： 1018-8665            Impact factor:   5.366


  3 in total

Review 1.  SPIRIT-PRO Extension explanation and elaboration: guidelines for inclusion of patient-reported outcomes in protocols of clinical trials.

Authors:  Melanie Calvert; Madeleine King; Rebecca Mercieca-Bebber; Olalekan Aiyegbusi; Derek Kyte; Anita Slade; An-Wen Chan; E Basch; Jill Bell; Antonia Bennett; Vishal Bhatnagar; Jane Blazeby; Andrew Bottomley; Julia Brown; Michael Brundage; Lisa Campbell; Joseph C Cappelleri; Heather Draper; Amylou C Dueck; Carolyn Ells; Lori Frank; Robert M Golub; Ingolf Griebsch; Kirstie Haywood; Amanda Hunn; Bellinda King-Kallimanis; Laura Martin; Sandra Mitchell; Thomas Morel; Linda Nelson; Josephine Norquist; Daniel O'Connor; Michael Palmer; Donald Patrick; Gary Price; Antoine Regnault; Ameeta Retzer; Dennis Revicki; Jane Scott; Richard Stephens; Grace Turner; Antonia Valakas; Galina Velikova; Maria von Hildebrand; Anita Walker; Lari Wenzel
Journal:  BMJ Open       Date:  2021-06-30       Impact factor: 2.692

2.  A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE).

Authors:  K A Papp; K Barber; R Bissonnette; M Bourcier; C W Lynde; Y Poulin; J Shelton; J Toole; A Vieira; M Poulin-Costello
Journal:  J Eur Acad Dermatol Venereol       Date:  2014-07-01       Impact factor: 6.166

3.  Two-year radiographic and clinical outcomes from the Canadian Methotrexate and Etanercept Outcome study in patients with rheumatoid arthritis.

Authors:  Edward C Keystone; Janet E Pope; J Carter Thorne; Melanie Poulin-Costello; Krystene Phan-Chronis; Andrew Vieira; Boulos Haraoui
Journal:  Rheumatology (Oxford)       Date:  2015-09-11       Impact factor: 7.580
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.